Literature DB >> 16427722

Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage.

Guido J Burbach1, Andreas Vlachos, Estifanos Ghebremedhin, Domenico Del Turco, Janaky Coomaraswamy, Matthias Staufenbiel, Mathias Jucker, Thomas Deller.   

Abstract

Passive immunization of amyloid precursor protein (APP) transgenic mice with anti-amyloid beta (Abeta) antibodies was shown to reduce Abeta-deposition in brain and to improve cognition. However, immunotherapy may also be accompanied by a significant increase in the frequency of intracerebral hemorrhages. Because hemorrhages are associated with amyloid-laden vessels, this raises the question whether high concentrations of anti-Abeta antibodies may directly or indirectly lead to a structural destabilization of the vessel wall. To address this point, transmission electron microscopy was performed and the ultrastructure of bleeding and non-bleeding vessels in immunized and non-immunized APP23 transgenic animals was analyzed. To localize bleeding vessels, hemosiderin-positive macrophages were visualized by pre-embedding Perl's Berlin Blue histochemistry. Vessels were analyzed morphologically, anomalies evaluated and quantified. Bleeding vessels were, furthermore, reconstructed in three dimensions to analyze the spatial distribution of amyloid deposits and other pathological changes of the vessel wall. This in-depth morphological analysis revealed that bleeding vessels in immunized as well as in non-immunized APP23 mice were surrounded by a higher number of macrophages compared to non-bleeding vessels in the same animals. However, no differences in the number of macrophages or other structural parameters, such as amyloid deposition, were observed between bleeding vessels of immunized and non-immunized mice. No pathologies which may indicate impending bleeding were observed in the vascular wall of non-bleeding vessels. We conclude, that the increased hemorrhage frequency observed after passive immunization with anti-Abeta antibodies does not lead to overt structural changes in the vessel wall of APP23 transgenic mice. Minor structural alterations of the vessel wall, however, cannot be excluded due to the sample size of our study and the high complexity of the three-dimensional vessel wall ultrastructure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16427722     DOI: 10.1016/j.neurobiolaging.2005.12.003

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  16 in total

Review 1.  Therapeutic strategies for Alzheimer's disease.

Authors:  Donna M Barten; Charles F Albright
Journal:  Mol Neurobiol       Date:  2008-06-26       Impact factor: 5.590

Review 2.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.

Authors:  Reisa A Sperling; Clifford R Jack; Sandra E Black; Matthew P Frosch; Steven M Greenberg; Bradley T Hyman; Philip Scheltens; Maria C Carrillo; William Thies; Martin M Bednar; Ronald S Black; H Robert Brashear; Michael Grundman; Eric R Siemers; Howard H Feldman; Rachel J Schindler
Journal:  Alzheimers Dement       Date:  2011-07       Impact factor: 21.566

Review 3.  CD4 T cells in immunity and immunotherapy of Alzheimer's disease.

Authors:  Alon Monsonego; Anna Nemirovsky; Idan Harpaz
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

4.  T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease.

Authors:  Yair Fisher; Anna Nemirovsky; Rona Baron; Alon Monsonego
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

5.  The biochemical aftermath of anti-amyloid immunotherapy.

Authors:  Chera L Maarouf; Ian D Daugs; Tyler A Kokjohn; Walter M Kalback; R Lyle Patton; Dean C Luehrs; Eliezer Masliah; James Ar Nicoll; Marwan N Sabbagh; Thomas G Beach; Eduardo M Castaño; Alex E Roher
Journal:  Mol Neurodegener       Date:  2010-10-07       Impact factor: 14.195

Review 6.  Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.

Authors:  Donna M Wilcock; Carol A Colton
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-03       Impact factor: 4.388

7.  Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice.

Authors:  Alexandra J Mably; Wen Liu; Jessica M Mc Donald; Jean-Cosme Dodart; Frédérique Bard; Cynthia A Lemere; Brian O'Nuallain; Dominic M Walsh
Journal:  Neurobiol Dis       Date:  2015-07-26       Impact factor: 5.996

Review 8.  Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.

Authors:  Hiroaki Taguchi; Stephanie Planque; Yasuhiro Nishiyama; Paul Szabo; Marc E Weksler; Robert P Friedland; Sudhir Paul
Journal:  Autoimmun Rev       Date:  2008-04-09       Impact factor: 9.754

9.  Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice.

Authors:  Jessica Koenigsknecht-Talboo; Melanie Meyer-Luehmann; Maia Parsadanian; Monica Garcia-Alloza; Mary Beth Finn; Bradley T Hyman; Brian J Bacskai; David M Holtzman
Journal:  J Neurosci       Date:  2008-12-24       Impact factor: 6.167

Review 10.  Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?

Authors:  Gregory A Jicha
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.